Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes
- Sponsor
- Rabin Medical Center
- Study ID
- NCT02016846
- Phase
- PHASE3
- Status
- Unknown
Conditions
- Glucocorticoid Induced Hyperglycemia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Liraglutide — DRUG
- Placebo — DRUG
Study Details
Glucocorticoids therapy exposes the patient to an increased risk for diabetes morbidity. However, there is no proven preventive therapy. GLP-1-RA has shown to improve glucose metabolism in healthy volunteers treated with glucocorticoids. We assume that GLP-1-RA will improve glucose metabolism in patients with high risk for diabetes morbidity, treated with glucocorticoids.
Key Dates
- Start date
- Jan 31, 2014
- Status verified
- Dec 2013
- Primary completion
- Jan 31, 2015
Study Design
- Enrollment
- 36 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Placebo Comparator: Placebo
- Active Comparator: InterventionLiraglutide, tapered from 0.6 mg/day to 1.8 mg/day.
Primary Outcome Measure
Glucose levels 2 hours after 75 gr OGTT [ Time Frame: 6 weeks ]
Central Contacts
- Amit Tirosh, MD+972.50.8191078